The treatment, Dupixent, was approved May 20 to treat eosinophilic esophagitis in adults and pediatric patients 12 and older weighing at least 88 pounds.
Dupixent is a monoclonal antibody that helps stop part of the inflammatory pathway of the esophagus in those with the disease, the release said.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
